Manni Mohyuddin Profile picture
Apr 14 19 tweets 5 min read Twitter logo Read on Twitter
The correct answer to this question was smoldering myeloma.

Time for an educational 🧵for trainees/health care folks of all specialties about how we diagnose myeloma!

What are CRAB criteria? How is anemia defined? (Key to this Q)

Whats the deal with "SLiM" criteria?

#mmsm
What are CRAB features?

Hypercalcemia
Anemia
Lytic Bone Lesions
Renal Failure

Anemia is defined as a Hb value of 2 g/dL or 20g/L below lowest limit of normal for the lab, or less than 10g/DL (100g/L)

Is there something magical however about a Hb of 10.1 versus 9.9?
This is where we recognize that there is some arbitrariness/clinical decision making involved.

In general, very mild anemia such as this case would not qualify as a CRAB criteria, and this would be referred to as smoldering myeloma.
Also, sometimes anemia can be from causes other than myeloma. Especially if the plasma cell burden is low (10-20%), must evaluate for other causes of anemia and alternate explanations. Sometimes you can have smoldering myeloma with iron deficiency anemia, or MGUS with anemia!
55 yr old gentleman with HTN, DM, CKD and a long standing creatinine of ~2-3 mg/DL develops neuropathy.

Workup shows M spike 1.2 g/DL.

K/L ratio is abnormal at 12. Bone marrow biopsy shows 15% plasma cells. PET/CT/MRI neg. Kidney biopsy with diabetic changes.

Diagnosis?
The correct answer here is smoldering myeloma.

Why?

More than 10% plasma cells (less than 10% would be MGUS territory)

And no CRAB/SLiM features that you can attribute to the myeloma.

The elevated creatinine is attributed to diabetes.

This is important to recognize!
Since we are talking creatinine, what is the creatinine value as defined in CRAB?

Renal insufficiency is defined as creatinine clearance <40 mL per minute or serum creatinine >177mol/L (>2mg/dL).
What about hypercalcemia?

While hypercalcemia is rarely isolated manifestation of myeloma, the high calcium level must be >0.25 mmol/L (>1mg/dL) higher than the upper limit of normal or >2.75 mmol/L (>11mg/dL).

Now lets talk about the SLiM features

Often a source of confusion!
57 yr old gentleman on routine labs found to have elevated protein.

CBC Normal, CMP normal other than total protein= 9.3 g/DL.
M spike=2.1 g/DL.
K/L ratio= 12
Bone marrow biopsy= 15% monoclonal plasma cells
Skeletal survey= Negative

Diagnosis?
The correct answer to this question is that further advanced imaging is needed.

A skeletal survey can miss up to 40% of lytic lesions that would otherwise be picked up via advanced imaging such as MRI, low dose whole body CT or PET/CT!
You now proceed with a whole body diffusion weighted MRI (myeloma MRI).

You find no lytic lesions, but you do find two focal bone marrow lesions, one measuring 1.2 cm, and another measuring 0.8 cm.

Diagnosis?
A common source of confusion are focal bone marrow lesions on MRI versus "lytic lesion".

Focal lesions are early, abnormal areas in bone marrow seen on MRI that signal the development of a full-on lytic lesion within the next few years.

Different than an "actual lytic lesion"!
In 2014, the definition of myeloma changed to include these as myeloma defining event:

-more than 1 focal bone marrow lesion of at least 5 mm on MRI
-involved/uninvolved light chain ratio of grt than 20
-bone marrow plasma cell % of grt than 60

These are called SLiM criteria!
So above patient has MM, because of presence of focal bone marrow lesions, even in absence of other CRAB features.

The three aforementioned findings were added because the risk of MM was felt to be 70-80% in the next two years for such patients based on limited data at that time
Now the reality is that as more data has accumulated, the actual risk of progression of these patients has found to be much lower.

More in the ballpark of 30% in next two years, as opposed to 80%!

pubmed.ncbi.nlm.nih.gov/36969337/
Hence today, there is some controversy with treating those with SLiM criteria alone (no CRAB features) too!

This thread is getting long and should come to an end, so we must summarize key findings!
⭐️The degree of anemia matters. Not all mild anemia in setting of plasma cell clonality is myeloma!
⭐️Degree of renal dysfunction matters too. Not all renal dysfunction is related
⭐️ A focal bone marrow lesion on MRI is different than a "lytic" lesion. Both can diagnose MM though
Thanks for reading. Cannot capture all nuances but hopefully helpful for trainees and other specialties!

@AaronGoodman33 @nihardesai7 @HemOncFellows @rajshekharucms @Eddie_Cliff @HadidiSamer @TheFellowOnCall

END.
Involved/uninvolved light chain ratio of greater than 100*

Not 20.

Sorry for the error!

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Manni Mohyuddin

Manni Mohyuddin Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ManniMD1

Mar 21
The carfilzomib (K) versus bortezomib (V) saga for newly diagnosed myeloma.

An educational, historical and philosophical thread.

#mmsm
V was first approved by the FDA in 2004.

K approved in 2013.

As opposed to V, K is an "irreversible" PI- and is much more active against myeloma cell lines compared to V

(note=pre-clinical efficacy is NOT clinical efficacy- melflufen was 50x more potent than melphalan 🧐!) Image
For a me-too drug to be useful it must offer at least one of the following features:

1) It works when original drug stops working
2) It has more "clinical" efficacy (not just againt cell lines) than original drug
3) It is safer/has different adverse events than the original drug
Read 22 tweets
Mar 1
I congratulate the team who worked diligently to produce the PANGEA model to predict myeloma risk

This is the first "dynamic" model that assesses risks, and in my opinion is a step forward from existing models.

Some thoughts in 🧵

#mmsm

thelancet.com/journals/lanha…
Firstly, I commend the team for choosing a trainee (@anniencowan ) as a first author. So inspirational. I saw that for the PROMISE study too, @HabibElKhoury was first author).

This is the way 👏
I also admit I am not a statistician, and this was a very technical read. The results and methods are not an easy read for a clinician. I will focus my comments on the clinical aspect of things, because some of the stats in this manuscript are simply over my head.
Read 15 tweets
Feb 15
Our work on quality of content of oncology news websites just out:

bit.ly/3Sf2OJz

Major team effort led by @NamSharmaMD with input from @AaronGoodman33 @ColeWayant @VPrasadMDMPH, Chris Booth, @KarunNeupaneMD and my wise friend and pt advocate @MyelomaAmateur

🧵👇
Non-paywalled link:

drive.google.com/file/d/1ezKC3D…

(This is a pre-proof, final PDF pending)
We analyzed all content that came on OncLive and Targeted Oncology during October 2021.

We used previously validated criteria (journals.plos.org/plosone/articl…) to analyze the quality of the content on these websites.
Read 9 tweets
Feb 13
The first investigator initiated randomized trial that I am a principal investigator on is now open to enrollment! Yay

Using budesonide to reduce diarrhea during auto-transplant in pts with myeloma, as well as robust QOL assessment during auto!

clinicaltrials.gov/ct2/show/NCT05…

Brief 🧵
Diarrhea is amongst the worst of side effects that patients experience during auto-SCT. The majority of patients experience Grade 2 or higher diarrhea, defined as at least 4-6 bowel movements above baseline that may impair IADLs.

It profoundly impacts quality of life.
Although a minority of patients may have infections, the vast majority of the time diarrhea is due to the toxic effects of chemotherapy on intestinal epithelium.

Currently, we use anti-motility drugs to treat diarrhea, as well as maintaining fluid balance, checking for infxn.
Read 14 tweets
Feb 10
The first randomized trial of CAR-T in multiple myeloma.

nejm.org/doi/full/10.10…
Ide-cel versus a choice of five regimens for relapsed multiple myeloma!

Lots to learn and process from this trial- so let us get started with this deep-dive 🧵

#mmsm
What was the intent/purpose of this trial?

This was not necessarily aimed for us to figure out what the best option is for patients with 2-4 prior lines of therapy, but to fulfill regulatory requirements for approval (given prior approval was based on single arm study).
What was the patient population enrolled in this study?

Had to have 2-4 prior lines of therapy.
84% had prior auto
65% triple refractory
6% penta-refractory.

No clear single best standard of care in this population-important to highlight.
Read 23 tweets
Feb 8
My approach to transplant for myeloma (some nuance lost):
Young stnrd-risk who prioritizes PFS: Upfront auto
Young stnrd-risk who doesn't prioritize PFS: Defer
Young high-risk: Upfront auto
Older high-risk: Transplant only if mel200 can be given
Older standard risk: No auto
#mmsm
3 trials and supporting evidence in brief thread:

1)DETERMINATION: PFS benefit, but no OS at 7-8 years of follow-up, despite low cross-over in control arm
nejm.org/doi/full/10.10…
2)IFM-2009: PFS benefit, but no OS benefit at 7-8 years, although high-cross over to transplant in control arm

nejm.org/doi/full/10.10…
Read 8 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(